期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

大剂量化疗联合自体造血干细胞移植治疗复发、难治性边缘区非霍奇金淋巴瘤疗效观察 被引量：2

High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory marginal zone non-Hodgkin＇ s lymphoma
原文传递
导出
摘要 目的评价大剂量化疗联合自体造血干细胞移植治疗复发、难治性边缘区淋巴瘤的价值。方法回顾性分析12例接受大剂量化疗或放化疗联合自体造血干细胞移植治疗的复发、难治性边缘区淋巴瘤患者的临床资料。结果12例患者中，1例发生治疗相关性死亡，1例在移植后出现复发，4例死于非肿瘤相关性疾病；中位无进展生存期104个月，中位总生存期117个月；6例患者尚无病生存。结论大剂量化疗联合自体造血干细胞移植治疗复发、难治性边缘区淋巴瘤有效，尤其适用于对利妥昔单抗联合化疗不敏感的患者。 Objective To evaluate the role of high-dose chemotherapy combined with autologous hematopoietie stem cell transplantation in relapsed/refractory marginal zone lymphomas. Methods The transplant database was reviewed retrospectively from Tianjin Medical University Cancer Hospital identified 12 patients who underwent high-dose chemotherapy combined with autologous hematopoietie stem cell transplantation. Results Among the twelve patients who underwent autologous hematopoietic stem cell transplantation, the median duration of progression-free survival （PFS） was 104 months and the median duration overall survival （OS） was 117 months; 6 patients were still alive with disease-free. Conclusion High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation is feasible to patients with relapsed/refractory marginal zone lymphomas, particularly to those insensitive to rituximabincluded combined chemotherapy.
作者 盂祥睿 王华庆 崔秀珍
机构地区 天津医科大学附属肿瘤医院淋巴瘤内科天津市"肿瘤防治"重点实验室中美淋巴血液肿瘤诊疗中心
出处 《白血病．淋巴瘤》 CAS 2012年第10期595-597,共3页 Journal of Leukemia & Lymphoma
关键词 造血干细胞移植 淋巴瘤 B细胞 边缘区 复发 难治 Hematopoietic stem cell transplantation Lymphoma, B-cell, marginal zone Relapsed Refractory
分类号 R329.2 [医药卫生—人体解剖和组织胚胎学]
  • 相关文献

参考文献18

  • 1Swerdiow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues.4th ed. Lyon: IARC Press, 2008: 185-188.
  • 2Li L, Bierman P, Vose J, et al. High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk, 2011, 11:253-256.
  • 3达永,张伟京,苏航,陈喜林,仲凯励,余金得,俞受程.利妥昔单抗联合化疗治疗CD_(20)^+的B细胞型非霍奇金淋巴瘤27例[J].白血病．淋巴瘤,2006,15(5):371-372. 被引量：9
  • 4沈元元,王会平,张翠,丁士华,张薇,翟志敏.利妥昔单抗治疗老年人脾边缘区淋巴瘤二例并文献复习[J].白血病．淋巴瘤,2011,20(4):247-249. 被引量：4
  • 5Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin's lymphoma: a phase II trim in the North Centerl Cancer Treatment Group. Leuk Lymphoma, 2008, 49:1074-1080.
  • 6Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa- associated lymphoma tissue lymphoma treated with radiation therapy has excellent chinical outcome. J Clin Oncol, 2003, 21: 4157-4164.
  • 7Montalban C, Sant6n A, Redondo C, et al. Long-term persistence of molecular disease after histological remission in low-grade gastric MALT lymphoma treated with Helicobacter pylori eradication. Lack of association with translocation t (11;18): a 10-year updated follow-up a prospective study. Ann Oncol, 2005, 16: 1539-1544.
  • 8Raderer M, Streubel B, WShrer S, et al. High relapse rate in patients with MALT lymphoma warrants life long follow-up. Clin Cancer Res, 2005,11:3349-3352.
  • 9Raderer M, Wfihrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa -associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol, 2006, 24: 3136-3141.
  • 10Hitchcock S, Ng AK, Fisher DC, Silver B, et al. Treatment outcome of mucosa-associated lymphoid tissue/marginal zone non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 2002, 52: 1058-1066.

二级参考文献12

  • 1Ferreri AJ,Zucca E.Marginal-zone lymphoma.Cirt Rev Oncol Hematol,2007,63:245-246.
  • 2Hermine O,Lefrère F,Bronowicki JP,et al.Regression of splenic lymphoma with villous lymphocytes after treatment of hematitis C virus infection.N Engl J Med,2002,347:89-94.
  • 3Troussard X,Valersi F,Duchayne E,et al.Splenic lymphoma with villous lymphocytes:clinical presentation,biology and prognostic factors in a series of 100 patient.Br J Haematol,1996,93:731-736.
  • 4Mateo M,Mollejo M,Villuendas R,et al.7q31-32allelic loss is a frequent finding in splenic marginal zone lymphoma.Am J Pathol,1999,154:1583-1589.
  • 5Algara P,Mateo MS,Sanchez-Beato M,et al.Analysis of the IgV(H)somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course.Blood,2002,99:1299-1304.
  • 6Murakami H,Irisawa H,Saitoh T,et al.Immunological abnormalities in splenic marginal zone cell lymphoma.Am J Hematol,1997,56:173-178.
  • 7Tsimberidou AM,Catovsky D,Schlette E,et al.Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy lone.Cancer,2006,107:125-135.
  • 8Forero A,Lobuglio AF.History of antibody therapy for non-Hodgkin's lymphoma.Semin Oncol,2003,30:1-5.
  • 9Czuzman M S,Grillo-Lopez A J,White C A,et al.Treatment of patients with low-grade B-cell lymphoma with the combination of chimericanti-CD20 monoclonal antibody and CHOP chemotherapy[J].J Clin Oncol,1999,17(3):268-276.
  • 10Vose J M,Link B K,McLaughlin B P,et al.Phase Ⅱ study of rituximab in combination with CHOP chemotherapy in patients with previously untreated,aggressive non-Hodgkin's lymphoma[J].J Clin Oncol,2001,19(5):389-397.

共引文献11

同被引文献64

引证文献2

二级引证文献6

白血病．淋巴瘤
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部